Tirzepatide – 10 vials (TR5) is a new medication that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is used in the treatment of type 2 diabetes and is currently being studied to evaluate its potential benefits in weight management.
Available in multiple dosages:


Reviews
There are no reviews yet.